Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage

Annals of the American Thoracic Society

Volumn 10, Issue 6, 2013, Pages 727-729

  Junpaparp, Parichart ^a   Sharma, Bhavna ^a   Samiappan, Ambiga ^a   Rhee, Ji Hyun ^a   Young, K Randall ^a  

^a ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; HEMOGLOBIN; LEVOFLOXACIN; METHYLPREDNISOLONE; PREDNISONE;

ACUTE RESPIRATORY FAILURE; AGED; ARTIFICIAL VENTILATION; BRONCHOSCOPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRACKLE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EXTUBATION; FEMALE; HUMAN; HYPOXEMIA; LETTER; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG LAVAGE; LUNG LOBE; LUNG TOXICITY; RESPIRATORY TRACT INTUBATION; THORAX RADIOGRAPHY; WHEEZING;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEMORRHAGE; HUMANS; LUNG DISEASES; LUNG INJURY; NEOPLASM RECURRENCE, LOCAL; SIROLIMUS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892156182     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201309-332LE     Document Type: Letter

References (7)

1. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, et al.; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
2. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-529.
3. Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer (In press)
4. Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy: a meta-Analysis of published trials. Acta Oncol 2012;51:873-879.
5. Fielhaber JA, Carroll SF, Dydensborg AB, Shourian M, Triantafillopoulos A, Harel S, Hussain SN, Bouchard M, Qureshi ST, Kristof AS. Inhibition of mammalian target of rapamycin augments lipopolysaccharide-induced lung injury and apoptosis. J Immunol 2012;188:4535-4542.
6. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest 2010; 137:456-459.
7. Depuydt P, Nollet J, Benoit D, Praet M, Caes F. Fatal acute pulmonary injury associated with everolimus. Ann Pharmacother 2012;46:e7.